Sapien 3 Performs Well in “Jobs” for Which It Is Not Designed

Using Sapien 3, transcatheter mitral valve replacement to treat failed bioprosthetic valves can be performed with a high degree of technical success.

Buen desempeño de la Sapien 3 en “trabajos” para los que no está diseñada

Failed mitral bioprosthetic valves are truly challenging due to how frequent symptoms are and the high morbidity/mortality associated with a new surgical replacement. Furthermore, there are no catheter options specifically designed to treat this issue.

Sapien 3 was developed as a last resource, but thanks to its good results, it is becoming a consistently good option.

Researchers analyzed prospectively all patients implanted with Sapien 3 to treat a failed mitral prosthesis between 2015 and 2019 included in the Society of Thoracic Surgeons (STS) registry. The primary efficacy endpoint was 1-year mortality, and secondary endpoints included 30-day mortality, New York Heart Association functional class, and valve performance.


Read also: Convalescent Plasma for Severe Pneumonia from COVID-19.


A total of 1529 patients were included; they had undergone a mitral valve-in-valve procedure through transseptal or transapical access in 295 sites. Technical success was achieved in 96.8% of patients and 30-day and 1-year mortality rates were 5.4% and 16.7%, respectively.

Transseptal access was linked to lower 1-year mortality compared with transapical access (15.8% vs. 21.7%; p = 0.03). 

New valve implantation provided immediate and sustained symptomatic relief. Baseline New York Heart Association functional class was III/IV in 87.1% of patients vs. 9.7% after a year.

Conclusion

Transcatheter mitral valve replacement in failed mitral bioprosthetic valves was associated with high technical success, lower 30-day/1-year mortality rates, and significant improvement of heart failure symptoms.

This option should be considered for most patients with failed mitral bioprosthetic valve and favorable anatomy.

Original Title: One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve.

Reference: Brian Whisenan et al. JAMA Cardiol. 2020;5(11):1245-1252. doi:10.1001/jamacardio.2020.2974.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

 The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...